All In Biotech

Drug Trial Radar · NCT07339176

Intratumoral N17350 in Advanced Solid Tumors

A Phase 1/2 Open-Label, Dose Finding and Expansion Study to Investigate the Safety and Effectiveness and Determination of the Optimal Dose of N17350 Administered Intratumorally in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

275

Planned (sponsor's estimate)

Start

May 25, 2026

Primary completion

Jul 2028

Study completion Nov 2029

Sponsor

Lead sponsor
Onchilles Pharma IncIndustry
Sponsor type
Industry
Collaborators
Onchilles Pharma Pty Ltd
First posted
Jan 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best dose to use in future studies. The main questions it aims to answer are: 1. Does N17350 cause tumors to shrink or stop growing in some participants with advanced solid tumors? 2. Are there any side effects for participants when taking N17350? 3. What is the safest dose of N17350 and the dose that should be used for further study? 4. Researchers will give N17350 directly into tumor lesions using a needle (intratumoral injection). This is an open-label study, meaning all participants will receive N17350 and there is no placebo. Participants will: 1. Receive injections of N17350 into tumor lesions every second week for 8 or 12 weeks 2. Visit the clinic regularly for checkups, blood tests, and monitoring for side effects 3. Have imaging scans (such as CT or MRI) to measure tumors and assess response 4. Provide blood samples and, when required, tumor samples to help researchers understand how N17350 affects the tumor and the immune system

Conditions

  • Neoplasms, Solid Tumor
  • Breast Neoplasms, Triple-Negative
  • Squamous Cell Carcinoma of Skin
  • Melanoma
  • Head and Neck Neoplasms
  • Carcinoma, Squamous Cell
  • Carcinoma, Non-Small-Cell Lung

Interventions

  • N17350Biological

    N17350 is a recombinant mutant porcine pancreatic elastase (PPE) developed to target the neutrophil elastase (ELANE) pathway.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Safety and tolerability of intratumoral N17350, including incidence of DLTs and adverse eventsTime frame: DLTs: First 28 days; TEAEs/SAEs/laboratory abnormalities: From enrollment through 30 days after last dose assessed up to 4 months
  2. Phase 2: Objective Response Rate (ORR) of lesions at RP2D/optimal dose(s)Time frame: From baseline disease assessment until disease progression or initiation of a new anticancer therapy, assessed up to 15 months

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • The Angeles Clinic and Research Institute

    Los Angeles, California · Not yet recruiting

  • UCLA - Jonsson Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Scripps Clinic Torrey Pines - La Jolla

    San Diego, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Not yet recruiting

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Calvary Mater Hospital

    Newcastle, New South Wales, Australia · Recruiting

  • Westmead Hospital

    Westmead, New South Wales, Australia · Recruiting

  • Peter MacCallum Cancer Centre (PMCC)

    Melbourne, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.